Back to Search
Start Over
Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Mar 15; Vol. 12, pp. 635166. Date of Electronic Publication: 2021 Mar 15 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- The extracellular matrix (ECM) molecule Tenascin-C (TNC) is well-known to promote tumor progression by multiple mechanisms. However, reliable TNC detection in tissues of tumor banks remains limited. Therefore, we generated dromedary single-domain nanobodies Nb3 and Nb4 highly specific for human TNC (hTNC) and characterized the interaction with TNC by several approaches including ELISA, western blot, isothermal fluorescence titration and negative electron microscopic imaging. Our results revealed binding of both nanobodies to distinct sequences within fibronectin type III repeats of hTNC. By immunofluroescence and immunohistochemical imaging we observed that both nanobodies detected TNC expression in PFA and paraffin embedded human tissue from ulcerative colitis, solid tumors and liver metastasis. As TNC impairs cell adhesion to fibronectin we determined whether the nanobodies abolished this TNC function. Indeed, Nb3 and Nb4 restored adhesion of tumor and mesangial cells on a fibronectin/TNC substratum. We recently showed that TNC orchestrates the immune-suppressive tumor microenvironment involving chemoretention, causing tethering of CD11c+ myeloid/dendritic cells in the stroma. Here, we document that immobilization of DC2.4 dendritic cells by a CCL21 adsorbed TNC substratum was blocked by both nanobodies. Altogether, our novel TNC specific nanobodies could offer valuable tools for detection of TNC in the clinical practice and may be useful to inhibit the immune-suppressive and other functions of TNC in cancer and other diseases.<br />Competing Interests: MM was employed by Colzyx AB. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Dhaouadi, Ben Abderrazek, Loustau, Abou-Faycal, Ksouri, Erne, Murdamoothoo, Mörgelin, Kungl, Jung, Ledrappier, Benlasfar, Bichet, Chiquet-Ehrismann, Hendaoui, Orend and Bouhaouala-Zahar.)
- Subjects :
- Animals
Antibodies, Neutralizing pharmacology
Antibody Specificity
Binding Sites, Antibody
Cell Adhesion drug effects
Cell Line, Tumor
Colitis, Ulcerative immunology
Colon immunology
Enzyme-Linked Immunosorbent Assay
HEK293 Cells
Humans
Immunohistochemistry
Liver Neoplasms immunology
Liver Neoplasms secondary
Protein Binding
Single-Domain Antibodies pharmacology
Tenascin administration & dosage
Tenascin immunology
Antibodies, Neutralizing immunology
Camelus immunology
Single-Domain Antibodies immunology
Tenascin antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33790905
- Full Text :
- https://doi.org/10.3389/fimmu.2021.635166